secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001654954-24-014204
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI appoints Dr. Nabil Saba as lead for Phase III Multikine study in head and neck cancer
--------------------------------------------------------------------------------

- Dr. Saba will serve as global Phase III confirmatory trial lead and Study Steering Committee member for Multikine.
- He is a recognized head and neck cancer expert, professor at Emory, and has led over 50 clinical trials.
- Appointment positions CEL-SCI for its upcoming confirmatory registration study in newly diagnosed head and neck cancer.
- Dr. Saba chairs NCI head and neck cancer task forces and holds NIH funding for related research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495424014204/0001654954-24-014204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495424014204/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-014204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer